Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Leronlimab |
| Synonyms | |
| Therapy Description |
Leronlimab is a monoclonal antibody that targets CCR5, which potentially induces killing of tumor cells expressing CCR5, inhibits invasion and metastasis, and reduces tumor burden (Cancer Res 2020;80(4 Suppl):Abstract nr PD4-04). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Leronlimab | PRO140|PRO 140|anti-CCR5 antibody | Leronlimab is a monoclonal antibody that targets CCR5, which potentially induces killing of tumor cells expressing CCR5, inhibits invasion and metastasis, and reduces tumor burden (Cancer Res 2020;80(4 Suppl):Abstract nr PD4-04). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04504942 | Phase II | Leronlimab | Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | 0 |